399 results on '"Nivolumab -- Reports"'
Search Results
2. Researchers from Analysis Group Inc. Publish Findings in Kidney Cancer (Long-Term Temporal Trends of Real-World Healthcare Costs Associated with Nivolumab Plus Ipilimumab and Pembrolizumab Plus Axitinib as First-Line Treatment for Advanced or ...)
3. St James's University Hospital Researcher Targets Lymphoma (Paradigm Shifts in Hodgkin Lymphoma Treatment: From Frontline Therapies to Relapsed Disease)
4. University of Chicago Researchers Provide New Data on Head and Neck Cancer (Acquired resistance to immunotherapy and chemoradiation in MYC amplified head and neck cancer)
5. B-Cell Non-Hodgkin Lymphoma Clinical Trials and Studies: EMA, PDMA, FDA Approvals, Mechanism of Action, ROA, NDA, IND, and Companies
6. Perioperative Nivolumab Tops Chemo for Survival in Resectable Lung Cancer
7. Researchers at Netherlands Cancer Institute Target Science (Spatial relationships in the urothelial and head and neck tumor microenvironment predict response to combination immune checkpoint inhibitors)
8. Research on Cancer Vaccines Discussed by Researchers at Ardabil University of Medical Sciences (A literature review of recent advances in gastric cancer treatment: exploring the cross-talk between targeted therapies)
9. Researchers from Dana-Farber Cancer Institute Report Findings in Kidney Cancer (First-line Systemic Therapy Following Adjuvant Immunotherapy In Renal Cell Carcinoma: an International Multicenter Study)
10. Patent Issued for Anti-PD-L1 antibodies (USPTO 12180282)
11. Patent Issued for Use of glucocorticoid receptor modulators to potentiate checkpoint inhibitors (USPTO 12171760)
12. Norwegian Institute of Public Health Researchers Target Melanoma (From trials to practice: Immune checkpoint inhibitor therapy for melanoma patients in Norway)
13. Researchers Submit Patent Application, 'Gene Signature Of Ctcs To Detect Melanoma Brain Metastasis', for Approval (USPTO 20240410014)
14. Research from Netherlands Cancer Institute Yields New Findings on Non-Small Cell Lung Cancer (Blood platelet RNA profiles do not enable for nivolumab response prediction at baseline in patients with non-small cell lung cancer)
15. Patent Issued for Bispecific and monospecific antibodies using novel anti-PD-1 sequences (USPTO 12152076)
16. New Findings from H. Lee Moffitt Cancer Center and Research Institute in the Area of Cancer Gene Therapy Described (Neoadjuvant Intratumoral Plasmid IL-12 Electro-Gene-Transfer and Nivolumab in Patients with Operable, Locoregionally Advanced ...)
17. Findings from Dana-Farber Cancer Institute Yields New Data on Thyroid Cancer (Dual Immune Checkpoint Inhibition In Patients With Aggressive Thyroid Carcinoma: a Phase 2 Nonrandomized Clinical Trial)
18. Novel immunotherapy combo shows promise in melanoma
19. Researchers Submit Patent Application, 'Cancer Treatment Agent', for Approval (USPTO 20240342245)
20. Researcher from Health Science University Reports Recent Findings in Lung Cancer (Evaluating the Effectiveness of Nivolumab in Metastatic Lung Cancer Among Patients Aged 65 and Older)
21. Research Institute of Clinical Oncology Researchers Advance Knowledge in Papillary Adenocarcinoma (A rare tumour - metastatic digital papillary adenocarcinoma: literature review, clinical case of successful therapy)
22. Patent Application Titled 'Immunogenic Compounds For Cancer Therapy' Published Online (USPTO 20240342261)
23. Reports from South China University of Technology Describe Recent Advances in Thrombocytopenia (Signal detection of immune thrombocytopenia associated with immune checkpoint inhibitors)
24. Findings from Stanford University Provide New Insights into Genomics and Genetics (The Role of Response Adapted Therapy In the Era of Novel Agents)
25. Researcher at Lawrence Berkeley National Laboratory Zeroes in on Monoclonal Antibodies (Residue-Specific Epitope Mapping of the PD-1/Nivolumab Interaction Using X-ray Footprinting Mass Spectrometry)
26. Findings from All India Institute of Medical Sciences (AIIMS) Has Provided New Data on Carcinomas (Nivolumab and Cabozantinib Immunotherapy Induced Thyroid Dysfunction Detected On 18f-fdg Pet/ct In Renal Cell Carcinoma)
27. Cancer Institute Hospital of Japanese Foundation for Cancer Research Researchers Provide Details of New Studies and Findings in the Area of Adenocarcinoma (Safety and efficacy of first-line nivolumab plus chemotherapy for HER2-negative advanced ...)
28. Patent Application Titled 'Antigenic Peptides For Prevention And Treatment Of Cancer' Published Online (USPTO 20240293520)
29. Data on Anemia Discussed by Researchers at Nagoya City University Graduate School of Medical Sciences (External validation of hemoglobin and neutrophil levels as predictors of the effectiveness of ipilimumab plus nivolumab for treating renal ...)
30. National Cancer Center Hospital East Researchers Add New Data to Research in Rectal Cancer (VOLTAGE-2: multicenter phase II study of nivolumab monotherapy in patients with mismatch repair-deficient resectable locally advanced rectal cancer)
31. Lack of Insurance Keeps Many Americans From Best Cancer Meds
32. Nivolumab Combo for Untreated Advanced Urothelial Carcinoma Ups Survival
33. Add-On Durvalumab Possibly Beneficial in Muscle-Invasive Urothelial Carcinoma
34. Maria Sklodowska-Curie National Research Institute of Oncology Researchers Reveal New Findings on Melanoma (Modern Approach to Melanoma Adjuvant Treatment with Anti-PD1 Immune Check Point Inhibitors or * * BRAF/MEK* * Targeted Therapy: ...)
35. New Colon Cancer Study Findings Reported from Eisenhower Health (Immune checkpoint inhibition in advanced colorectal cancer with inherited and acquired microsatellite instability: Current state and future directions)
36. New Rectal Cancer Research from National Cancer Center Hospital East Discussed [Correlation of enriched specific subset of immune cells nearby tumor associated macrophage (TAM) with pathologic complete response (pCR) of concurrent ...]
37. Researchers Submit Patent Application, 'Biomarker For Predicting Response To Cancer Treatment', for Approval (USPTO 20240264158)
38. University of Texas MD Anderson Cancer Center Researcher Advances Knowledge in Adenoid Cystic Carcinoma [Axitinib plus avelumab for recurrent/metastatic adenoid cystic carcinoma (R/M ACC): Biomarker analysis of the phase II trial]
39. Reports from West China Second University Hospital Add New Study Findings to Research in Cervical Cancer (Immunotherapy for Recurrent and Metastatic Cervical Cancer: A Review)
40. Research on Rectal Cancer Discussed by a Researcher at Government College University Lahore (Dostarlimab: A promising new PD-1 inhibitor for cancer immunotherapy)
41. Researchers Submit Patent Application, 'Anti-Pd-1 Polypeptides And Their Use', for Approval (USPTO 20240239892)
42. Researchers Submit Patent Application, 'Inducible Cytokine Prodrug And Pd-1/Pd-L1 Combination Therapy', for Approval (USPTO 20240216505)
43. Researchers Submit Patent Application, 'Combination Therapy for Metastatic Cancer', for Approval (USPTO 20240216308)
44. Researcher from National Cancer Center Hospital Details Findings in Non-Small Cell Lung Cancer [Randomized phase III study comparing suspension or continuation of PD-1 pathway blockade for patients with advanced non-small-cell lung cancer (SAVE ...]
45. Miami Cancer Institute Researcher Publishes Findings in Astrocytomas (A phase II, open label, single arm study of nivolumab for recurrent or progressive IDH mutant gliomas with prior exposure to alkylating agents)
46. Albert Einstein College of Medicine Researchers Detail Research in Non-Small Cell Lung Cancer (Advancing neoadjuvant therapies in resectable non-small cell lung cancer: implications for novel treatment strategies and biomarker discovery)
47. Researchers Submit Patent Application, 'Bcl-2 Inhibitors', for Approval (USPTO 20240180924)
48. University of Calgary Researchers Provide Details of New Studies and Findings in the Area of Melanoma (Imaging response to immune checkpoint inhibitors in patients with advanced melanoma: a retrospective observational cohort study)
49. Research on Cancer Reported by a Researcher at Jamia Millia Islamia (Nivolumab and Ipilimumab Acting as Tormentors of Advanced Tumors by Unleashing Immune Cells and Associated Collateral Damage)
50. Reports from Eisenhower Health Describe Recent Advances in Lung Cancer (A case of palmar-plantar erythrodysesthesia in a lung cancer patient receiving atezolizumab maintenance)
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.